Mr. Wit has been a member of the Board of Directors since November 1999. He currently serves as our Executive Chairman. He was CEO from June of 2002 until June 2017. Previously, he was the President of Corporate Finance at Noesis Capital Corp, Boca Raton, Florida, a NASD member firm, from March 1995 until May 2002. Prior to 1994, Mr. Wit was the CEO for DMV, USA, the American subsidiary of Campina Melkunie, a Dutch multibillion dollar food and pharmaceutical ingredients company. He also served as Vice President of International Operations for Duphar, a pharmaceutical company in Holland. Mr. Wit graduated from Nyenrode, a business university in Holland.
Mr. Smith has been an executive officer and member of the Board of Directors since 1997. He currently serves as our Executive Vice Chairman. He served as President and Chief Technology Officer from May 1997 until August 2000 and thereafter as Chairman and Chief Technology Officer until June 2017. From December 1995 to May 1997, he was Director of Operations for Global Communications Group. Mr. Smith received a B.S. from Purdue University.
Adam Cohen graduated in Pharmacy and Medicine from Leiden University. He subsequently joined the department of Clinical Pharmacology of the Wellcome Research Laboratories where he obtained experience in early drug development as well as larger trials. He obtained a Ph.D. from Leiden University (1986). He spent a training period in internal medicine and nephrology in King’s College Hospital London. Since 1987, he has been Director of the Centre for Human Drug Research (CHDR), a research centre for early drug development and proof of concept studies in healthy subjects and patients. He is Professor of Clinical Pharmacology at Leiden University and has a clinical attachment at the department of nephrology at Leiden University Medical Centre. Between 1999 and 2011, he was Vice-Chairman of the Central Ethics Committee and the Competent Authority (CCMO) of the Netherlands and is European Editor of the British Journal of Clinical Pharmacology as well as a member of the Health Council of the Netherlands and the Council for Medical Sciences of the Royal Academy of Sciences of the Netherlands. Dr. Cohen was also one of the founders of Promasys BV, which was acquired by OmniComm Systems.
Gary A. Shangold, M.D., FACOG, CPI, is Founder and President of the consulting firm Convivotech, LLC, and of the startup specialty pharmaceutical company InteguRx Therapeutics LLC. Dr. Shangold joined the OmniComm Systems board in July 2014. He has previously served in various capacities with a number of other pharmaceutical companies: Chief Medical Officer at Xanodyne Pharmaceuticals Inc.; President and CEO of NovaDel Pharma Inc.; Vice President and Regulatory Head of Drug Development at Johnson & Johnson Pharmaceutical Research & Development LLC; Senior Director of Gynecologic and Reproductive Clinical Research at RW Johnson Pharmaceutical Research Institute; and Medical Director at Serono Laboratories Inc. He also served as Chair of the Board of Trustees for the Association of Clinical Research Professionals and currently serves on their Nominating and Executive Committees. His extensive clinical experience brings a deep industry perspective to the OmniComm Board which enables him to advise the board on regulatory and drug development issues surrounding the clinical trial industry.
Mr. Schweitzer has been a member of the Board of Directors since August 2013. Mr. Schweitzer spent his career in the financial services industry as head of lending divisions at money center and major regional banks, Regional President of two major regional banks, and CEO and Chairman of two community banks. He also served as President of a major regional investment bank. He is a graduate of the U.S. Naval Academy, served on nuclear submarines and retired with the rank of Captain, and holds an MBA from the University of North Carolina. He currently serves on three other public company boards and is Chairman of two.